EAST BRUNSWICK, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2008 following the close of the market on Wednesday, November 5, 2008.
Christopher Clement, President and Chief Executive Officer and Brian Hayden, Senior Vice President and Chief Financial Officer will host an investment community conference call beginning at 10:00 a.m. Eastern Time on November 6, 2008 to discuss these results and to answer questions.
Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Savient Pharmaceuticals' web site at http://www.savient.com. To listen to the live call, please go to the web site fifteen minutes prior to its start to register, download, and install the necessary audio software.
A replay will be available on the web site. A telephone replay will be available from 12:00 p.m. Eastern Time on November 6, 2008 through 11:59 p.m. Eastern Time on November 20, 2008 by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering conference ID number 67897749.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals is a biopharmaceutical company engaged in
developing and distributing pharmaceutical products that target unmet
medical needs in both niche and broader markets. The company's product
development candidate, Puricase(R) (pegloticase) for treatment-failure
gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing
in the Phase 3 clinical studies began in June 2006; patient enrollment was
completed in March 2007; and the
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved